Moderna (MRNA) Tops Q2 EPS by 2c; cuts revenue guidance

Moderna (NASDAQ: MRNA) reported Q2 EPS of ($3.33), $0.02 better than the analyst estimate of ($3.35). Revenue for the quarter came in at $241 million versus the consensus estimate of $128.41 million.

GUIDANCE:

Moderna sees FY2024 revenue of $3-3.5 billion, versus the consensus of $3.83 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Occidental Petroleum releases Q2 2026 earnings considerations
• What Delta’s report tells investors in American and United
• Niagen Bioscience files to sell up to $50M in common stock